Flight attendants may have higher cancer rates
(Reuters Health) - U.S. flight attendants may be more likely than other Americans to develop several types of cancer including tumors of the breast, uterus, cervix, thyroid and skin, new research suggests. (Source: Reuters: Health)
Source: Reuters: Health - June 26, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Flight Attendants Have Higher Rates of Many Cancers, Study Says
Flight attendants are exposed to a number of known cancer-causing risks, but few studies have rigorously quantified that risk, and researchers say they are an understudied occupational group.
The Harvard Flight Attendant Health Study (FAHS), begun in 2007, addresses some of the gaps in understanding health risks among flight attendants. In the latest report, published in the journal Environmental Health, researchers found that flight attendants had higher rates of many cancers, including breast cancer and melanoma, compared to the general population.
The FAHS included more than 5,300 flight attendants who were recruited th...
Source: TIME: Health - June 26, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer healthytime Source Type: news
US flight attendants at elevated risk of several forms of cancer
(Harvard T.H. Chan School of Public Health) US flight attendants have a higher prevalence of several forms of cancer, including breast cancer, uterine cancer, gastrointestinal cancer, thyroid cancer, and cervical cancer, when compared with the general public, according to new research from Harvard T.H. Chan School of Public Health. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 25, 2018 Category: Cancer & Oncology Source Type: news
Power morcellation: Questions linger for controversial tech
Dr. Amy Reed’s tragic case brought to light the cancer risks posed by power morcellation. Her death hasn’t stopped lingering questions about the technology.
Power morcellators were used for 20 years to laparoscopically remove fibroids, benign tumors of the uterus, raising not a single adverse event report with the FDA. That all changed in 2013, when Dr. Amy Reed, an attending physician at Beth Israel Deaconess Medical Center, underwent a myomectomy using power morcellation at nearby Brigham & Women’s Hospital.
Reed’s fibroids were not benign, but instead a malignant form of cancer called uterine sarcoma...
Source: Mass Device - June 1, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Gynecological Legal News News Well Recalls Regulatory/Compliance Surgical Cancer eximissurgical johnsonandjohnson powermorcellators Source Type: news
Obesity may make women more vulnerable to a host of cancers, especially if they gain weight quickly
Compared to women of normal weight, those with obesity are 24% more likely to develop one of a handful of cancers linked to the condition, and their chances of developing cancers of the kidney or endometrium were around twice as high as those of normal-weight women, new research has found.In a... (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - May 23, 2018 Category: Science Authors: Melissa Healy Source Type: news
Study: Uterine cancer survivors have greater risk of cardiovascular problems
Survivors of uterine cancer are more likely to face cardiovascular problems several years after treatment, according to a study. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 8, 2018 Category: Consumer Health News Source Type: news
Uterine cancer survivors are more likely to have cardiovascular problems
(Oxford University Press USA) A new study in the Journal of the National Cancer Institute indicates that survivors of uterine cancer are more likely to experience cardiovascular problems years after treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 8, 2018 Category: Cancer & Oncology Source Type: news
UCLA research may explain some causes of infertility and miscarriage
A new study in the journal Nature Cell Biology has uncovered information about a key stage that human embryonic cells must pass through just before an embryo implants. The research, led by UCLA biologist Amander Clark, could help explain certain causes of infertility and spontaneous miscarriage.Infertility affects around 10 percent of the U.S. population, and roughly 15 to 20 percent of all pregnancies in the U.S. end in miscarriage. In many cases, the causes of infertility and miscarriage are unknown.A team led by Clark, a UCLA professor of molecular cell and developmental biology and member of the Eli and Edythe Broad ...
Source: UCLA Newsroom: Health Sciences - April 25, 2018 Category: Universities & Medical Training Source Type: news
MRI helps distinguish fibroids from uterine cancer
T2-weighted MR images are effective for distinguishing between uterine fibroids...Read more on AuntMinnie.comRelated Reading:
Fewer women are getting hysterectomies
SIR: Women unaware of UFE as fibroid treatment option
Study: UFE can help restore fertility
SIR: UFE use still lags hysterectomy for fibroids
Under scrutiny: Pregnancy after uterine fibroid embolization (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 25, 2018 Category: Radiology Source Type: news
TIME 100 ’s Giuliano Testa: We Should Think About Infertility As a ‘Wellbeing Issue’
Dr. Giuliano Testa, a transplant surgeon at Baylor University Medical Center at Dallas who led the medical team that performed the first successful uterus transplants in the United States, said Tuesday that he hopes “what we are doing is going to shed light on infertility for women.”
“I personally never knew it was such a widespread issue,” Testa said at the TIME 100 Gala on Tuesday. “We should be thinking about it not just as a birth, but a wellbeing issue.”
Testa attended the TIME 100 Gala after being named by TIME magazine as one of the most influential people in the world for his rol...
Source: TIME: Health - April 24, 2018 Category: Consumer Health News Authors: Alexandra Sifferlin Tags: Uncategorized onetime T1002018 Source Type: news
New Drug Combo Ups Survival in HER2/neu Uterine Serous Cancer
WEDNESDAY, April 18, 2018 -- For patients with human epidermal growth factor receptor 2 (HER2)/neu-positive uterine serous carcinoma, adding intravenous trastuzumab to treatment with carboplatin-paclitaxel is associated with increased... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 18, 2018 Category: Pharmaceuticals Source Type: news
New drug combo improves survival of women with rare uterine cancer
(Johns Hopkins Medicine) Adding the monoclonal antibody drug trastuzumab -- already used to treat certain breast cancers -- to the chemotherapy regimen of women with a rare form of uterine cancer lengthens the amount of time their tumors are kept from growing, according to Johns Hopkins Medicine researchers conducting a small phase II trial of the regimen, testing its safety and value (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 10, 2018 Category: Cancer & Oncology Source Type: news
Embolx wins $2m NIH grant for pressure-directed embolization therapy
Embolx said today that it landed a $2 million grant from the National Cancer Institute to fund development of its next-generation Sniper balloon occlusion microcatheter.
The Sunnyvale, Calif.-based medical device company has developed a drug-delivery system that administers therapies into targeted areas of the body by controlling pressure. Embolx’s Sniper balloon is designed to treat cancerous tumors, benign prostatic hyperplasia and uterine fibroids, according to the company.
Get the full story at our sister site, Drug Delivery Business News.
The post Embolx wins $2m NIH grant for pressure-directed embolization th...
Source: Mass Device - April 6, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Funding Roundup Pharmaceuticals Research & Development embolx National Institutes of Health (NIH) Source Type: news
Does Trastuzumab Plus Carbo/Paclitaxel Up PFS in Advanced HER2+ Uterine Carcinoma?
At SGO 2018, an early study showed ‘encouraging’ PFS with trastuzumab added to combination carboplatin/paclitaxel for advanced HER2/neu-overexpressing uterine serous carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - March 30, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Gynecologic Cancers News Conferences/SGO Source Type: news
